Lonza Group AG (LZAGF)
USD 740.0
(3.79%)
USD 740.0
(3.79%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 1.58 Billion CHF | -12.86% |
| 2022 | 1.81 Billion CHF | 21.19% |
| 2021 | 1.5 Billion CHF | 32.13% |
| 2020 | 1.13 Billion CHF | -18.39% |
| 2019 | 1.39 Billion CHF | 11.36% |
| 2018 | 1.25 Billion CHF | 6.2% |
| 2017 | 1.17 Billion CHF | 31.22% |
| 2016 | 897 Million CHF | 0.45% |
| 2015 | 893 Million CHF | -0.56% |
| 2014 | 898 Million CHF | 20.21% |
| 2013 | 747 Million CHF | 0.0% |
| 2012 | 747 Million CHF | -3.36% |
| 2011 | 773 Million CHF | 56.16% |
| 2010 | 495 Million CHF | -14.21% |
| 2009 | 577 Million CHF | -4.47% |
| 2008 | 604 Million CHF | 0.0% |
| 2007 | 604 Million CHF | 24.02% |
| 2006 | 487 Million CHF | -18.83% |
| 2005 | 600 Million CHF | 10.29% |
| 2004 | 544 Million CHF | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 1.71 Billion CHF | 0.0% |
| 2024 Q1 | 1.71 Billion CHF | 8.14% |
| 2023 Q4 | 1.58 Billion CHF | 0.0% |
| 2023 Q1 | 1.93 Billion CHF | 6.21% |
| 2023 FY | 1.58 Billion CHF | -12.86% |
| 2023 Q3 | 1.58 Billion CHF | -17.96% |
| 2023 Q2 | 1.93 Billion CHF | 0.0% |
| 2022 Q2 | - CHF | 0.0% |
| 2022 Q4 | 1.81 Billion CHF | 0.0% |
| 2022 FY | 1.81 Billion CHF | 21.19% |
| 2022 Q1 | - CHF | -100.0% |
| 2022 Q3 | 1.81 Billion CHF | 0.0% |
| 2021 FY | 1.5 Billion CHF | 32.13% |
| 2021 Q3 | 1.5 Billion CHF | 0.0% |
| 2021 Q2 | - CHF | 0.0% |
| 2021 Q1 | - CHF | -100.0% |
| 2021 Q4 | 1.5 Billion CHF | 0.0% |
| 2020 Q3 | 1.13 Billion CHF | 0.0% |
| 2020 Q2 | - CHF | 0.0% |
| 2020 Q4 | 1.13 Billion CHF | 0.0% |
| 2020 Q1 | - CHF | -100.0% |
| 2020 FY | 1.13 Billion CHF | -18.39% |
| 2019 Q1 | - CHF | -100.0% |
| 2019 Q3 | 1.39 Billion CHF | 0.0% |
| 2019 FY | 1.39 Billion CHF | 11.36% |
| 2019 Q2 | - CHF | 0.0% |
| 2019 Q4 | 1.39 Billion CHF | 0.0% |
| 2018 Q3 | 1.25 Billion CHF | 0.0% |
| 2018 Q1 | - CHF | -100.0% |
| 2018 Q4 | 1.25 Billion CHF | 0.0% |
| 2018 FY | 1.25 Billion CHF | 6.2% |
| 2018 Q2 | - CHF | 0.0% |
| 2017 Q4 | 1.17 Billion CHF | 0.0% |
| 2017 FY | 1.17 Billion CHF | 31.22% |
| 2017 Q2 | - CHF | 0.0% |
| 2017 Q1 | - CHF | -100.0% |
| 2017 Q3 | 1.17 Billion CHF | 0.0% |
| 2016 Q3 | 897 Million CHF | 0.0% |
| 2016 Q1 | - CHF | -100.0% |
| 2016 FY | 897 Million CHF | 0.45% |
| 2016 Q2 | - CHF | 0.0% |
| 2016 Q4 | 897 Million CHF | 0.0% |
| 2015 Q1 | - CHF | -100.0% |
| 2015 Q4 | 893 Million CHF | 0.0% |
| 2015 Q2 | - CHF | 0.0% |
| 2015 Q3 | 893 Million CHF | 0.0% |
| 2015 FY | 893 Million CHF | -0.56% |
| 2014 FY | 898 Million CHF | 20.21% |
| 2014 Q1 | - CHF | -100.0% |
| 2014 Q2 | - CHF | 0.0% |
| 2014 Q3 | 898 Million CHF | 0.0% |
| 2014 Q4 | 898 Million CHF | 0.0% |
| 2013 Q4 | 747 Million CHF | 0.0% |
| 2013 FY | 747 Million CHF | 0.0% |
| 2013 Q3 | 747 Million CHF | 0.0% |
| 2013 Q2 | - CHF | 0.0% |
| 2013 Q1 | - CHF | -100.0% |
| 2012 Q2 | - CHF | 0.0% |
| 2012 FY | 747 Million CHF | -3.36% |
| 2012 Q4 | 747 Million CHF | 0.0% |
| 2011 FY | 773 Million CHF | 56.16% |
| 2011 Q4 | 773 Million CHF | 0.0% |
| 2011 Q2 | - CHF | 0.0% |
| 2010 Q4 | 495 Million CHF | 0.0% |
| 2010 Q2 | - CHF | 0.0% |
| 2010 FY | 495 Million CHF | -14.21% |
| 2009 Q4 | 577 Million CHF | 0.0% |
| 2009 FY | 577 Million CHF | -4.47% |
| 2009 Q2 | - CHF | 0.0% |
| 2008 Q4 | 604 Million CHF | 0.0% |
| 2008 FY | 604 Million CHF | 0.0% |
| 2007 FY | 604 Million CHF | 24.02% |
| 2006 FY | 487 Million CHF | -18.83% |
| 2005 FY | 600 Million CHF | 10.29% |
| 2004 FY | 544 Million CHF | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| American Bio Medica Corporation | 379 Thousand USD | -418105.805% |
| Arrayit Corporation | 464.19 Thousand USD | -341353.536% |
| Atlantic International Corp. | - USD | -Infinity% |
| Biocept, Inc. | 757 Thousand USD | -209279.128% |
| Bioqual, Inc. | - USD | -Infinity% |
| CardioGenics Holdings Inc | -2385.00 USD | 66457123.061% |
| DermTech, Inc. | 1 Million USD | -157768.526% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 3.29 Million USD | -47943.246% |
| HTG Molecular Diagnostics, Inc. | 909.32 Thousand USD | -174204.541% |
| iMD Companies, Inc. | 38.31 Thousand USD | -4136553.095% |
| IDenta Corp. | 442.28 Thousand USD | -358269.453% |
| Interpace Biosciences, Inc. | 1.22 Million USD | -129076.854% |
| Integrative Health Technologies, Inc. | - USD | -Infinity% |
| InVitro International | 163.13 Thousand USD | -971487.949% |
| Lumos Diagnostics Holdings Limited | 784 Thousand USD | -202068.367% |
| Many Bright Ideas Technologies Inc. | -375.00 USD | 422666766.667% |
| Medical Imaging Corp. | - USD | -Infinity% |
| NovelStem International Corp. | - USD | -Infinity% |
| Optigenex Inc. | 468.77 Thousand USD | -338016.022% |
| PharmChem, Inc. | 391.93 Thousand USD | -404301.728% |
| Proteome Sciences plc | 1.06 Million USD | -148656.313% |
| Response Genetics, Inc | 133 Thousand USD | -1191629.323% |
| Rennova Health, Inc. | 242.64 Thousand USD | -653117.664% |
| RushNet, Inc. | - USD | -Infinity% |
| ScreenPro Security Inc. | 73.89 Thousand USD | -2144777.329% |
| Stella Diagnostics Inc. | - USD | -Infinity% |
| StageZero Life Sciences Ltd. | 95.62 Thousand USD | -1657485.677% |
| Todos Medical Ltd. | 1.02 Million USD | -155140.113% |